These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25407255)

  • 1. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Murphy J; Curtin C; Mamidi RN; Weiner S; Wang SS; Ariyawansa J; Stieltjes H; Wajs E; Di Prospero NA; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):115-28. PubMed ID: 25407255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
    Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
    J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
    Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
    Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
    Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
    Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
    Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.